Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041574 · ClinicalTrials.gov registry record · Phase 2
Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide
A Phase 2 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00041574 is a Phase 2 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 7 participants.
The verdict
NCT00041574, a Phase 2 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this program is to evaluate the logistic issues and patient requirements for chronic pulsed INOmax delivery in ambulatory, home-care patients. To understand patient needs, patients with a variety of underlying diseases will be included. Safety of chronic therapy will be monitored by serial measurements of methemoglobin, platelet function assay and reported adverse events.
Interventions
- DRUG Inhaled Nitric Oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2002-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041574
The ClinicalTrials.gov registry entry for NCT00041574 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Nitric Oxide is the first listed.
NCT00041574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041574 about?
NCT00041574 is a clinical study titled "Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide". The purpose of this program is to evaluate the logistic issues and patient requirements for chronic pulsed INOmax delivery in ambulatory, home-care patients. To understand patient needs, patients with a variety of underlying diseases will be included. Safety of chronic therapy will be monitored by s...
What is the current status of trial NCT00041574?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2002-04. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00041574?
The interventions under investigation include: Inhaled Nitric Oxide (DRUG).
Who is sponsoring clinical trial NCT00041574?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.